MedTrace Logo

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

NCT00849069 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-10-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.

Conditions

  • Haemophilus Influenzae
  • Streptococcus Pneumoniae

Interventions

BIOLOGICAL

GSK2231395A

3 doses intramuscular injections

BIOLOGICAL

TwinrixTM

3 doses intramuscular injections

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-12
Primary Completion
2009-04-07
Completion
2009-04-07

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849069 on ClinicalTrials.gov